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Abstract 
Aim: The present study attempts to 
determine the steps for obtaining the 
etiological diagnosis of brain metastases 
with unknown origin.  
Material and methods: A total of 190 
patients with brain metastases diagnosed in 
the Department of Neurosurgery in 
Emergency Hospital ”N. Oblu” Iasi 
between 2007-2010 were included in this 
study. The clinical characteristics and 
pathological features were analyzed. 
Results: There were 102 males and 88 
females with a M:F ratio of 1.15:1. The 
median age of patients was 47.07 years 
(range 31-77 years). Females patients were 
older (mean age 57.21 years) than males 
patients (49.15 years). 154 patients (81.05%) 
had single brain metastasis, and 36 patients 
(18.95%) had more than two. The lesions 
were supratentorial in 142 patients 
(74.73%), infratentorial in 18 (9.47%), and 
both infratentorial and supratentorial in 30 
patients (15.78%). Surgical treatment 
involved complete resection in 47.9% of 
cases, subtotal resection in 26.8%, and 
biopsy alone  in the remainder (25.3%). 
Brain metastases originating in lung cancer 
represented the most common type 
(47.39%), followed by those from breast 
cancer (19.79%), then those from skin 
(melanoma) (8.33%), genitourinary 
carcinoma (6.30%), and gastrointestinal 
carcinoma (2.62%). In 16.31% of cases, the 
primary tumor remained unknown, despite 
extensive investigation. 
Conclusion: The primary cancer leading 
to brain metastases can be detected either 
by obtaining a sample of tumoral tissue 
through a neurosurgical operation on the 
intracerebral tumor (total ablation or 
stereotactic biopsy) with histopathological 
examination, or by additional tests of the 
whole body. Taken into consideration the 
results of our own study, the management 
of the patients with brain metastases should 
include a thoracic CT scan or 
anteroposterior and lateral chest X-ray, 
clinical breast examination and 
mammography, abdominal ultrasound 
exploration, and skin, kidney and prostate 
examination. With the most sophisticated 
methods of diagnosis in approximately 16% 
of cases the origin of metastasis remains 
unknown. The identification of the primary 
site by the neuropathologist after 
stereotactic biopsy would clearly be 
advantageous. 
Keywords: brain metastases, cerebral 
cancer treatment, stereotactic biopsy, 
tumoral type 
 
 
 
Romanian Neurosurgery (2011) XVIII 1: 60 – 67          61 
 
 
 
Of all intracranial neoplasms, brain 
metastases represent 13.5-41% of all cases 
(4). Although most of these metastatic brain 
tumors can have a known primary site such 
as lung or breast carcinoma, there remaines 
a number of cases in which a thorough 
search failed to identify the primary site 
even at autopsy (26). Brain metastases of 
unknown origin become more frequently a 
problem for neurosurgeons as the 
expansion of computed tomograph (CT) 
network makes possible a cranio - cerebral 
exploration for any patient with 
neurological symptoms (20).  
Intraparenchymal metastases are usually 
well-defined round masses, often with 
nodular or ring enhancement (due to 
central necrosis) and with peritumoral 
edema. If multiple masses are seen, the 
diagnosis is much easier (4). 
Magnetic resonance imaging (MRI) with 
gadolinium is more sensitive than 
computed tomography for confirming the 
presence of brain metastases (18). It reveals 
single brain metastases in 1/3 of cases and 
multiple tumors in the remainders (28).  
Thus, for patients complaining of 
indistinctive symptoms such as headache, 
dizziness, nausea or vomiting, a CT scan 
can provide the surprising discovery of a 
brain tumor which proves to be a metastasis 
after completion of exploration. From a 
clinically point of view, such a brain tumor 
can manifest through a major inaugural 
neurological symptom, such as localized or 
generalized seizures. The third situation is 
the discovery of such a brain tumor 
through a CT screening. In all these cases 
the patients did not complain of any other 
organ symptoms and they haven’t been 
registered with a cancer (1).  
This report details the experience at the 
Neurosurgery Department of  “Prof. dr. N. 
Oblu” Clinic Emergency Hospital, Iasi, in 
the management of patients in whom the 
only evidence of malignancy at presentation 
was the metastatic disease of the brain. The 
aim of the present study was to evaluate this 
patient group in order to develop guidelines 
for further diagnostic and treatment 
procedures.  
Material and method 
Between 2007-2010, 190 consecutive 
patients with brain metastases, but with 
unknown primary site and no other 
evidence of metastases were treated in the 
Neurosurgery Department of  “Prof. dr. N. 
Oblu” Clinic Emergency Hospital, Iasi. 
All the patients were admitted in the 
hospital due to a previous general and 
neurological screening. Imaging 
investigation (CT or MRI) confirmed the 
diagnosis of a brain metastasis and gave 
information about their number. Surgical 
removals or stereotactic biopsies were 
carried out in all of them.  
A search for the primary site of the 
tumor  was made in each case during 
hospital stay. These included detailed 
history taking, thorough physical 
examination, routine chest radiographs, 
urine and blood investigations. Also, tissue 
samples taken through surgical removal or 
stereotactic biopsy have been processed in 
the Department of Pathology of the same 
hospital using the standard 
histopathological technique. Microscopical 
examinations have been done in all cases in 
order to determine the tumoral type of 
cerebral neoplasia and to identify the 
primary cancer due to some 
histopathological similarity between 
metastases and their “parental” 
malignancies.  
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Results 
Personal experience in the Neurosurgery 
Service of the Hospital “N. Oblu” Iasi 
showed that in a three years period of time 
have been diagnosed 190 patients with 
cerebral metastasis. There were 102 males 
and 88 females with a M:F ratio of 1.15:1. 
The mean age of entire population was 
47.07 years with a range of 31 – 77 years. 
Females ranged in age from 49 to 77 years 
with a mean of  57.21 years, whereas males 
had a mean age of 49.15 years with a range 
of 31 to 75 years. The highest incidence of 
brain metastases was in the sixth and 
seventh decades of life (Table 1). 
Brain CT was performed in 135 patients 
(71.05%), MRI in 36 patients (18.94%), and 
CT plus MRI in 19 (10%). 154 patients 
(81.05%) had single brain metastasis, and 36 
patients (18.95%) had more than two. The 
lesions were supratentorial in 142 patients 
(74.73%), infratentorial in 18 (9.47%), and 
both infratentorial and supratentorial in 30 
patients (15.78%). 
Surgical treatment involved complete 
resection in 47.9% of cases, subtotal 
resection in 26.8%, and biopsy alone  in the 
remainder (25.3%).  
Primary malignancies were diagnosed 
after surgical removal. Taken all cases 
together, brain metastases originating in 
lung cancer represented the most common 
type (47.39%) (Figures 1 and 2), followed 
by those from breast cancer (19.79%), then 
those from skin (melanoma) (8.33%) 
(Figure 3), genitourinary carcinoma 
(6.30%), and gastrointestinal carcinoma 
(2.62%). In 16.31% of cases, the primary 
tumor remained unknown, despite 
extensive investigation (Table 2). 
 
TABLE 1 
Brain metastases frequency by patients' age 
Age 
(years) 
30-39  40-49  50-59  60-69 70-79  Total 
No. of 
cases 
12 23 65 74 16 190 
Percentage 6.31% 11.97% 34.21% 38.54% 8.33% 100% 
TABLE 2 
Brain metastases frequency by primary cancer site 
Organ of 
origin 
Lung  Breast Skin Colo- 
rectum 
Stomach Testicul 
 
Prostate Kidney Unknown 
No. of  
cases 
91 38 16 3 2 3 7 2 31 
Per –centage 
(%) 
47.39 19.79 8.33 1.57 1.05 1.57 3.68 1.05 16.31 
 
 
Figure 1 Smear of a brain metastasis originating in 
an epidermoid squamocelullar carcinoma of the lung 
(toluidine blue, 10x20) 
 
Figure 2 Microphotograph of the microscopic 
features of a brain metastasis originating in a papillary 
carcinoma of the lung (Hematoxylin&Eosin, 10x10) 
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Figure 3 Histologic features of a brain metastasis 
from an epithelioid melanoma of skin (Hematoxylin-
eosin, 10x20) 
Discussion 
In 33-66% of patients, solitary cerebral 
metastasis give rise to the symptoms 
preceding even the primary lesion. 
Furthermore, in a significant number of 
cases the primary malignancy can not be 
diagnosed during life and in some cases 
remains unknown even at autopsy (26). 
The incidence and primary source of brain 
metastases vary with patient age. The 
highest incidence of brain metastases (over 
60%) is observed in patients 50 to 80 years 
old. In our study, the highest incidence of 
all cerebral metastases (72.75%) appeared in 
a younger group of patients (50-69 years) 
and the peak incidence (38.56%) was 
encountered in the sixth decade (50-59 
years). 
In the present research, there is no 
predilection of brain metastases for males or 
females. The histology of the primary 
cancer appears to be the major dictator of 
the frequency and pattern of intracranial 
extension. Virtually, any type of cancer has 
the ability to produce brain metastases. 
However, in decreasing relative frequency, 
lung cancer, breast cancer, melanoma, renal 
cancer, and colon cancer account for most 
brain metastases (27).  
In 1889, an English pathologist, Stephen 
Paget,  analysed the organ distribution of 
metastases produced by different human 
neoplasms in order to determine the 
pattern of metastasis process. He concluded 
that certain tumor cells (the “seed”) had a 
specific affinity for the milieu of certain 
organs (the “soil”) because metastases 
resulted only when the seed and soil were 
compatible (9). It is consider that 30% to 
60% of brain metastases originate from lung 
cancer (12). Breast cancer ranks second to 
lung cancer as the most frequently 
occurring primary tumor in patients with 
brain metastases. Among women, breast 
cancer is the most common cause of brain 
metastasis, resulting in 5% to 30% of all 
brain metastases (7). Melanoma ranks third 
among primary tumors giving rise to brain 
metastases. Of patients with brain 
metastases, approximately 5% to 21% will 
have melanoma as their primary tumor 
(29). Metastatic brain tumors from 
colorectal cancer are relatively rare, with a 
reported frequency of 1.8% to 4.8% of all 
metastatic brain metastases (24). Brain 
metastases from gastric cancer are 
extremely rare. Patients with gastric cancer 
account for less than 1% of all cases of brain 
metastases in autopsy and clinical series 
(27). Intracranial metastases from prostate 
cancer are rare (0.6% to 4.4% of cases) (8). 
The incidence of brain metastases in 
patients with testicular cancer ranges from 
2% to 25% in clinical series and was 20.7% 
in an autopsy series. However, brain 
metastases are extremely rare in surgical 
series of patients with testicular cancer (2%) 
(27). The incidence proportion of 
metastatic brain tumors from renal cancer 
in patients with primary renal tumors 
ranges from 5.5% to 11% (16) In 1999, 
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Taddei et al. investigated a group of patients 
with brain metastases with clinical 
characteristics similar with our study. In 
their group, made up of 211 patients with 
age ranging from 33 to 79 years, lung 
tumors (47%) and breast tumors (9%) were 
the most frequently responsible for brain 
metastases. In 17% of patients, the primary 
lesion was unknown (33). 
In our study, most of the patients with 
an identified underlying malignancy had a 
primary lung cancer (49.69%). This cancer 
also ranked first in other studies, although 
le Cesne et al found gastrointestinal 
tumours to be the most frequent (6).  
There are two possibilities to discover 
the location of primary cancer: 
• neurosurgical intervention and 
sampling of tumoral tissue in order to 
determine the histopathological features of 
tumoral architecture and tumoral cells; 
• general clinical examination and 
laboratory tests for discovery of primary 
neoplasm. 
Neurosurgical intervention may be 
classical ablation of the tumor or 
stereotactic biopsy. Total ablation 
intervention addresses to patients who have 
a good general state, single metastases, 
which is located in a non-eloquent area. In 
cases with multiple metastases total removal 
will address to the voluminous formation 
with herniation tendency. Indications for 
stereotactic biopsy refer to patients with 
deterioration of the general state, and with 
multiple metastases located in eloquent 
areas (Rolando area, central gray nuclei, 
corpus callosum, and brain stem). To 
obtain a valuable result it is necessary to 
make multiple samples within the tumor. 
As a consequence, fine needle biopsy could 
be a source of errors. 
After completing all explorations, 
including neurosurgical intervention, the 
discovery of the initial site of the primary 
cancer could rise to 85%. Pavlidis et al. (25) 
found that primary neoplasias remain 
unknown in 3% of all cases of cancers and 
Greco and Hainsworth (15) reported even 
less (2% of all cases). 
In our study, the primary site remained 
unknown in 16.44%patients, that represents 
a comparable group with those in other 
studies, in which the underlyning 
malignancy could not be detected in 15%-
50% of the patients with brain metastases. 
To have certainty it is mandatory to see a 
well-differentiated tumoral tissue that 
repeats the architecture of the tissue where 
the cancer developed initially. For poorly 
differentiated tumors, the origin of 
neoplasia couldn’t be identified. Moreover, 
there are two situations: in some cases 
existed similarity between the microscopic 
appearances of the brain metastasis and 
those of primary cancer, but in other cases 
the histopathological features of the brain 
metastasis does not coincide with those of 
the primary cancer. So, surgical 
intervention can offer a tumor sample that 
will be analyzed by the neuropathologist 
who could identify the histological type and 
the location of the primary cancer, but 
when there are poorly differentiated 
tumoral cells, than the pathological 
diagnosis could be difficult. In these cases it 
is necessary to use further investigations 
such as immunohistochemistry, electron 
microscopy and genetic analysis.  
A second possibility to identify the 
origin of a brain metastasis is to explore the 
whole body when there isn’t the necessity 
of an emergency operation for 
decompression. This is the situation of 
small brain metastases, with no tendency of 
herniation and no signs of intracranial 
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hypertension. 
The easier examination and more 
comfortable for the patient is a positron 
emission tomography (PET scan), but it has 
high costs. A study comprising  3000 
asymptomatic subjects have been found the 
existence of at least one brain metastasis in 
3% of cases. Brain metastases with 
unknown origin can be detected with 
Fluorodezoxyglucoze 18 (18F) which 
allowed the discovery of the primary cancer 
in 29% of cases (19, 22, 23). 
If there isn’t PET scan in the hospital, 
then it can be used classical explorations 
(radiograph, CT, MRI, laboratory testing). 
The ranking of these explorations could be 
based on statistics which showed how often 
can be encounter an organ as the origin of 
the primary cancer which can lead to a 
brain metastasis. Taken into consideration 
statistics from the literature (21) and the 
results of our own study, the management 
of the patients with brain metastases should 
include a thoracic CT scan or 
anteroposterior and lateral chest X-ray, 
clinical breast examination and 
mammography, abdominal ultrasound 
exploration, and skin, kidney and prostate 
examination. 
The treatment of brain metastases have 
to be complex in order to provide the 
longest survival for the patients (Figure 4). 
So, the management of brain metastases 
represents a formidably challenge. The first 
place in the panoply of treatment methods 
is neurosurgical complete removal of single 
metastases. The second method is the 
whole brain radiotherapy with or without 
pharmacological agents (such as motexafin 
gadolinium) which enhance the effect of 
radiation on brain metastases remnants 
(10). Another possibility for intracerebral 
metastases treatment is stereotactic 
radiosurgery which use several types of 
radiation-therapy devices: cobalt-60–based 
machines, linear accelerators, and 
cyclotrons, which use gamma rays,x-rays, 
and proton, respectively (32). It can be used 
also brachytherapy with Iodine - 125 (17) 
or laser induced thermal therapy (31). 
The goal of discovering the site of 
primary cancer would be the use of a 
specific type of chemotherapy for achieving 
cure of cerebral metastases. Unfortunately 
it should be noted that the existence of 
blood-brain barrier prevents chemotherapy 
drug action (9). However, there are studies 
(3) indicating the size reduction of brain 
metastases in some cases with lung or breast 
origin after using temozolomide, 
efaproxiral, metoxafin (13). In 
carcinomatous meningitis we can use 
intrathecal cytarabin and methotrexate (5). 
The maximum dose intravenous 
methotrexate also can be used (14).  
 When brain metastases are discovered, it 
should be initiated a symptomatic 
corticosteroid therapy and treatment for 
prevent seizures or thromboembolism. 
After interdisciplinary cooperation, primary 
cancer should be treat in tandem and in 
function of vital emergency. Complex 
treatment of cerebral metastases provides 
the longest survival. 
The median survival of patients with 
cerebral metastases would be 7 months 
when they are treated with whole brain 
radiotherapy, 15 months when 
radiosurgery is associated, 14 months 
when radiosurgery is used alone, 14 
months when brain radiotherapy is 
associated with surgical ablation, and 21 
months when all three treatment methods 
are used together (2, 11, 30, 34). 
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Algorithm of diagnosis and 
treatment 
Unknown Origin Cerebral metastasis 
High ger of engagement Little danger of engagement 
Ablation of dangerous 
metastasis emergency
PET-CT/General examination
Solitary metastasis
Surgery available
Ablation
Multiples metastasis
Surgery non-available
Stereotactic biopsy Radiosurgery
Treatment of origin cancer; Radiotherapy +/- chemotherapy                     
Symptomatic Treatment  
Figure 4 Algorithm of diagnosis and treatment for unknown origin cerebral metastases 
 
Depending on the number of cerebral 
metastases, it is noted that single metastasis 
treated by surgical ablation and 
radiotherapy has a median survival time of 
13 months while those multiple will have a 
median survival time of 7 months, with 0% 
survival at 2 years. Surgical ablation 
combined with radiosurgery offers an 
average survival of 10 months (15% 
surviving at 2 years).  
Conclusions 
The discovery of a brain metastasis in a 
routine computed tomography examination 
or for minor neurological symptoms 
become more frequently. The primary 
cancer leading to brain metastases can be 
detected either by obtaining a sample of 
tumoral tissue through a neurosurgical 
operation on the intracerebral tumor (total 
ablation or stereotactic biopsy) with 
histopathological examination, or by 
additional tests of the whole body. Taken 
into consideration the results of our own 
study, the management of the patients with 
brain metastases should include a thoracic 
CT scan or anteroposterior and lateral chest 
X-ray, clinical breast examination and 
mammography, abdominal ultrasound 
exploration, and skin, kidney and prostate 
examination. With the most sophisticated 
methods of diagnosis in approximately 16% 
of cases the origin of metastasis remains 
unknown. The identification of the primary 
site by the neuropathologist after 
stereotactic biopsy would clearly be 
advantageous. 
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